Release date: 2024-08-22 14:21:52 Article From: Lucius Laos Recommended: 148
Koselugo is a precisely targeted small molecule MEK inhibitor with a therapeutic focus on targeted therapies targeting specific tumor types, especially in the treatment of neurofibromatosis (NF1), demonstrating excellent efficacy and significant clinical application potential.
The recommended dose of Koselugo depends on the patient's body surface area, but the usual recommended dose is 25 mg/square meter of body surface area, taken orally twice daily in divided doses on an empty stomach. For patients with a large body surface area, such as more than 1.90 square meters, the daily dose can be increased to 50 mg in two divided doses.
The dose adjustment of Koselugo should be based on the specific situation of the patient and adverse reactions. For patients with moderate hepatic insufficiency, the recommended dose should be appropriately reduced to 20 mg/m² of body surface area twice daily.
In patients with severe hepatic insufficiency, no definitive recommended dose has been established and should be used with caution under the guidance of a physician. Concomitant use of Koselugo with strong or moderate CYP3A4 inhibitors should be avoided to avoid affecting drug metabolism and efficacy.
Patients should strictly follow the doctor's instructions when taking Koselugo and pay attention to monitoring relevant indicators.
The following indicators should be measured during Koselugo:
Koselugo may reduce the amount of blood pumped by the heart, and cardiac function tests should be performed regularly during use, including electrocardiogram, echocardiography, etc., to monitor changes in cardiac function.
Koselugo may cause vision problems, including blurred vision, blindness, etc., and should be checked regularly during use, and medical attention should be sought in time if there is any abnormality.
Regularly monitor biochemical indicators such as blood routine, liver function, and kidney function to evaluate the effects of drugs on the body.
In addition to the above-related indicators, patients should also pay attention to certain problems during medication.
The following are important things to keep in mind while taking Koselugo.
During the medication, the diet should be mainly light, avoid spicy and irritating food, and avoid alcohol or alcoholic beverages, so as not to affect drug metabolism and increase the risk of adverse reactions.
Patients should pay close attention to the changes in their symptoms, such as persistent coughing, wheezing, shortness of breath, swelling of the ankles and feet, fatigue, increased heart rate, blurred vision, blindness, floaters, and other symptoms of vision problems, should seek medical attention and inform the doctor of the medication.
The doctor may adjust the dosage of the drug according to the patient's specific situation and the effect of the treatment, and the patient should take the drug strictly according to the doctor's instructions, and should not increase or decrease the dose or stop the drug on their own.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: